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Diabetes mellitus is associated with left-sided myocardial remodeling in heart failure with 
preserved ejection fraction (HFpEF). Little is known about the impact of diabetes mellitus on 
right ventricular (RV) function in HFpEF. We therefore studied the relation between diabetes 
mellitus and RV dysfunction in HFpEF. We have examined HFpEF patients who underwent 
simultaneous right heart catheterization and echocardiography. RV systolic function was 
assessed using multiple established echocardiographic parameters and systolic dysfunction was 
present if ≥2 parameters were outside the normal range. RV diastolic function was assessed 
using the peak diastolic tricuspid annular tissue velocity (RV e’) and present if <8.0 cm/s. 
Diabetes mellitus was defined as documented history of diabetes, fasting glucose ≥7.0 mmol/L, 
positive glucose intolerance test or glycated hemoglobin  ≥6.5%. A total of 91 patients were 
studied; mean age 74±9 years; 69% women. A total of 37% had RV systolic dysfunction and 
23% RV diastolic dysfunction. 37% of the patients had type 2 diabetes mellitus. These patients 
had higher pulmonary artery pressure (34 vs. 29 mmHg, p=0.004), more RV systolic 
dysfunction (57 vs. 29%, p=0.009), more RV diastolic dysfunction (46 vs. 12%, p=0.001) and 
lower RV e’ (8.7 vs. 11.5 cm/s, p=0.006). The presence of diabetes mellitus was independently 
associated with RV systolic dysfunction [OR 2.84 (1.09-7.40) p=0.03] and with RV diastolic 
dysfunction [OR 4.33 (1.25-15.07) p=0.02], after adjustment for age, sex and pulmonary 
pressures. In conclusion, diabetes mellitus is strongly associated with RV systolic and diastolic 





Diabetes mellitus is a common comorbidity in patients with heart failure with preserved 
ejection fraction (HFpEF),(1,2) and is independently associated with increased morbidity and 
mortality.(2,3) Right ventricular (RV) dysfunction is also highly prevalent in HFpEF, is 
associated with a poor prognosis and is an important target for therapy in patients with 
HFpEF.(4-6) The exact mechanisms underlying the development of RV dysfunction in HFpEF 
are unclear and probably multifactorial, but an important determinant is pulmonary vascular 
disease resulting in pulmonary hypertension (PH).(7-9) Previous studies in individuals without 
heart failure have demonstrated that diabetes mellitus was associated with structural and 
functional remodeling of the RV.(10-12) Therefore, it can be speculated that in HFpEF the RV 
may also be affected by diabetes mellitus. More insight into these mechanisms may help to 
develop treatment strategies that target the right heart in HFpEF. We therefore sought to 
investigate the relation between diabetes mellitus and RV dysfunction in patients with HFpEF 
– with and without diabetes mellitus – who underwent simultaneous cardiac catheterization and 
echocardiography.  
METHODS 
The study cohort is previously described in detail.(7) In brief, 102 patients with HFpEF 
with LV ejection fraction ≥45% and New York Heart Association (NYHA) functional class ≥II 
were identified. These patients had echocardiographic signs of increased right-sided pressures 
and were therefore referred for left and right heart catheterization for evaluation of PH. 
Additional inclusion criteria for the present study were LV diastolic dysfunction (E/e’ ≥13 or 
mean e’ septal and lateral wall <9 cm/s) and/or left atrial (LA) dilatation (LA volume index 
≥34mL/m2 or LA parasternal diameter ≥45mm) and/or N-terminal of the pro-hormone brain 
natriuretic peptide (NT-proBNP) ≥125 ng/L.(13) Patients were excluded if there was no 
simultaneous echocardiographic assessment available. In addition, patients in whom RV 
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function could not be assessed reliably on echocardiography using at least two recommended 
parameters reflecting RV systolic function,(14) were excluded as well. 
Patients underwent a physical examination and laboratory testing, including glycated 
hemoglobin (HbA1c), estimated glomerular filtration rate (eGFR) and N-terminal of pro-B type 
natriuretic peptide (NT-proBNP). eGFR was calculated using the Modification of Diet in Renal 
Disease equation. 
Diabetes mellitus was defined as a documented history of diabetes, fasting plasma 
glucose ≥7.0 mmol/L, plasma glucose ≥11.1 mmol/L two hours after the oral glucose dose or 
HbA1c ≥6.5% (≥48 mmol/L).(15) Renal dysfunction was defined as eGFR <60 ml/min/kg. 
All patients included in the present study underwent left and right heart catheterization 
performed by a single experienced interventional cardiologist (E.S.H.). The invasive 
hemodynamic protocol used in our center is previously described in detail.(16) In brief, invasive 
measurements were performed with the patient in fasting state and in supine position. First, the 
system was zeroed at patients’ heart level. A 7F thermodilution balloon-tipped catheter was 
inserted through the femoral vein and advanced through the right atrium and RV into the 
pulmonary artery and wedge position. RV end-diastolic pressure, pulmonary artery pressures 
(PAP) and pulmonary capillary wedge pressure were obtained at end-expiration. Left heart 
catheterization was performed to exclude significant coronary artery disease or left-sided valve 
disease and LV end-diastolic pressure was measured. Cardiac output was calculated according 
to Fick. Pulmonary vascular resistance was subsequently calculated and expressed as 
dynes∙sec∙cm-5 and pulmonary arterial compliance was calculated using the volume 
method.(17) 
Echocardiographic images were acquired simultaneous with the cardiac catheterization 
using a Vivid S6 system (General Electric, Horton, Norway) using a 2.5- to 3.5-mHz probe. 
Analyses were independently performed by two blinded experienced investigators using GE 
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EchoPAC version BT12. Digitally stored images were used to measure the tricuspid annular 
plane systolic excursion (TAPSE) in M-mode on the apical 4-chamber view. In addition, both 
the peak systolic tissue velocity of the lateral tricuspid annulus (RV s’) and the peak diastolic 
tissue velocity of the lateral tricuspid annulus (RV e’) were assessed (Figure 1). RV fractional 
area change (FAC) using the apical 4-chamber view were assessed, according to current 
recommendations.(14) Finally, RV free wall longitudinal speckle-tracking strain was assessed 
as previously described with good inter- and intra-observer variability.(18) Each parameter was 
measured in duplicate at two time points and averaged to obtain one single value. Right 
ventricular systolic dysfunction was defined when at least two parameters for RV systolic 
function were below the lower recommended limit of normal (i.e. TAPSE <17 mm, RV s’ <9.5 
cm/s, RV FAC <35% and/or RV free wall longitudinal strain > -20%).(14) RV diastolic 
dysfunction was defined as RV e’ <8.0 cm/s.(19) Finally, RV Tei-index (i.e. RV index of 
myocardial performance) was calculated using the tissue Doppler method (i.e. isovolumetric 
time minus isovolumetric relaxation time, divided by total RV ejection time), as illustrated in 
Figure 1.(14) 
Data is described as mean ± standard deviation, median [25th-75th percentile] or numbers 
(percentages). Differences in continuous variables between two groups were tested using 
independent samples t-test or Mann-Whitney U-test, according to distribution. Differences in 
categorical variables between two groups were calculated using Chi-squared tests. Linear 
regression models were performed to test correlations between continuous variables. 
Unadjusted and adjusted analyses for the association between diabetes mellitus with the 
presence of RV systolic and diastolic dysfunction were performed using binary logistic 
regression models. In multivariable logistic regression analyses, the association between 
diabetes mellitus and RV systolic and diastolic dysfunction was adjusted for relevant covariates 
(i.e. age, sex, comorbidities, mean PAP, PVR and LV systolic and diastolic function). Due to 
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the small study sample, multiple logistic regression analyses were performed with no more than 
3 adjustment variables each. In addition, HbA1c (%) was correlated with the presence of RV 
systolic and diastolic dysfunction using binary logistic regression and odds ratios (OR) were 
depicted per standard deviation increase in HbA1c. Statistical significance was considered 
achieved with p-value <0.05 and all analyses were performed using SPSS (Version 23, 2015). 
RESULTS 
Of the initial population of 102 patients with HFpEF, 4 patients did not undergo 
simultaneous echocardiography and heart catheterization and were therefore excluded. Another 
7 patients were excluded because echocardiographic quality was insufficient for reliable 
assessment of RV systolic function. Therefore, a total of 91 patients were included in the present 
study. Characteristics of the population are described in Table 1. A total of 34 patients (37%) 
had type 2 diabetes mellitus and 6 of these patients had new onset diabetes with HbA1c ≥6.5% 
at the time of assessment. As seen in Table 1, patients with diabetes had higher body mass 
index and more often coronary artery disease, compared to HFpEF patients without diabetes. 
The former group of patients also had higher serum creatinine concentrations and lower eGFR. 
HFpEF patients with diabetes mellitus were also more symptomatic, as evidenced by more 
diuretic usage, higher NYHA functional class and lower percentage of predicted peak VO2.  
The echocardiographic and cardiac catheterization measurements are summarized in 
Tables 2 and 3. Right ventricular peak diastolic tissue velocity could be assessed in 83 patients 
(91%), and 19 of these (23%) had RV diastolic dysfunction (i.e. RV e’ <8.0 cm/s). Figure 2 
illustrates the correlation between left- and right-sided peak diastolic tissue velocities. RV e’ 
was correlated with both LV lateral e’ (Figure 2A) and septal e’ (Figure 2B).  
Patients with diabetes mellitus more often had RV systolic and diastolic dysfunction, 
compared to non-diabetic individuals (Table 2). In addition, RV end-diastolic pressure and 
mean PAP were higher in HFpEF patients with diabetes mellitus, compared to patients without 
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diabetes mellitus, while PVR was not significantly different between both groups (Table 3). In 
non-ischemic HFpEF (with exclusion of patients with coronary artery disease), RV systolic 
dysfunction remained more prevalent in patients with diabetes mellitus compared to those 
without (53 vs. 21%, respectively, p=0.02). 
In the logistic regression model (Table 4), diabetes mellitus was significantly associated 
with the presence of both RV systolic and diastolic dysfunction, after adjustment for all relevant 
covariates. As seen in Table 4, diabetes mellitus was also associated with higher RV end-
diastolic pressure, independent of these covariates, except for mean PAP.  
In addition, higher levels of HbA1c (%) were also associated with RV systolic dysfunction (OR 
1.88 [1.12-3.18] p=0.02) and RV diastolic dysfunction (OR 1.81 [1.06-3.10] p=0.03), although 
there was also a strong correlation between HbA1c and the presence of diabetes mellitus 
(β=0.61, p<0.001). 
In the present cohort, 25 patients (27.5%) had PVR >240 dynes/s/cm-5 and 13 (52%) of 
these patients had diabetes mellitus. In a secondary analysis in this subgroup of patients with 
high PVR, the patients with diabetes mellitus had more RV systolic dysfunction (85 vs. 42%, 
respectively, p=0.03), lower RV e’ (7.4 vs. 11.5 cm/s, respectively, p<0.001) and more RV 
diastolic dysfunction (67 vs. 0%, p<0.001), compared to the 12 patients without diabetes 
mellitus. Pulmonary vascular resistance was comparable in this subgroup between patients with 
and without diabetes mellitus (331 vs. 347 dynes/s/cm-5, respectively, p=0.44). 
DISCUSSION 
The present study demonstrated that RV systolic dysfunction was present in 37%, and 
RV diastolic dysfunction in 23% of HFpEF patients. Diabetes mellitus was strongly associated 
with both RV systolic and RV diastolic dysfunction, independent of RV afterload. To our 
knowledge, these findings are novel and add to the knowledge about the development of RV 
dysfunction in patients with HFpEF. 
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The observation that RV systolic dysfunction is prevalent in HFpEF, is in line with a 
large number of previous studies performed in patients with HFpEF and is strongly related to 
PH-HFpEF.(4,9) In a previous study, Gan et al. observed that RV diastolic function is impaired 
in patients with PH, and RV diastolic dysfunction could improve by reducing RV afterload with 
sildenafil.(20) Thus, RV diastolic dysfunction in HFpEF may also be related to longstanding 
increased afterload in the setting of PH-HFpEF. Interestingly, we observed that the presence of 
diabetes mellitus was also associated with both RV systolic and diastolic dysfunction in patients 
with HFpEF. There is evidence that comorbidities (including diabetes mellitus) contribute to 
endothelial dysfunction via release of inflammatory cytokines, increased levels of reactive 
oxygen species and decreased availability of nitric oxide.(21) Longstanding exposure to this 
oxidative stress and systematic inflammation in the setting of comorbidities are important 
mechanisms of the development of adverse myocardial remodeling and left ventricular diastolic 
dysfunction is one of its first manifestations.(21) Recently, Lindman et al. showed that HFpEF 
patients with diabetes mellitus indeed had a more severe phenotype of HFpEF, with increased 
risk of hospitalization, more advanced LV hypertrophy and higher concentrations of biomarkers 
that relate to oxidative stress, inflammation and fibrosis.(2) In the present study, we observed 
that HFpEF patient with diabetes had a higher prevalence of ischemic heart disease, higher use 
of diuretics and lower glomerular filtration rate. Nephropathy is an ominous sign in patients 
with diabetes, and is strongly associated with cardiac ischemia and diabetic 
cardiomyopathy.(22) Diabetic nephropathy may also have an important adverse impact on both 
ventricles simultaneously. 
Previously, Karamitsos et al. investigated RV diastolic function in young individuals 
with type I diabetes mellitus. These individuals without heart failure and no evidence of 
coronary artery disease or hypertension had higher transtricuspid E/A ratio and lower tricuspid 
annular e’, compared to healthy controls.(23) This suggests that, similar as for the LV, RV 
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diastolic dysfunction seems also an early sign of myocardial remodeling in diabetes mellitus. 
Also in patients with pulmonary arterial hypertension, diabetes mellitus is associated with 
reduced RV work load and lower survival rate, compared to non-diabetic individuals with 
pulmonary arterial hypertension.(24) In the present cohort in the subgroup of patients with high 
PVR, the patients with diabetes mellitus also had more RV systolic and diastolic dysfunction, 
while PVR was similar between both groups.  
Besides a direct myocardial effect, chronic hyperglycemia may also have an effect on 
pulmonary vascular remodeling ultimately resulting in right-sided pressure overload. For 
instance, Berthelot et al. included diabetes mellitus to a clinical risk model for the presence of 
PH in HFpEF.(25) We have recently shown that diabetes mellitus is more prevalent in HFpEF 
patients with combined post- and pre-capillary PH than in HFpEF patients with isolated post-
capillary PH.(7) In these patients, diabetes mellitus might enhance adverse pulmonary vascular 
disease through increased inflammation and reduced vasodilatation.(26) This hypothesis is 
supported by the fact that acute hyperglycemia (to glucose levels of 16.7 mmol/l) impairs 
endothelium-dependent vasodilation and lowers nitric oxide and prostacyclin in healthy, non-
diabetic individuals.(27)  
A hyperglycemic state could also be a plausible target for future treatment options. The 
phosphodiesterase type 5A inhibitor vardenafil, which enhances the vasodilator effects of cyclic 
guanosine monophosphate, was tested in Zucker diabetic fatty rats.(28) In this animal model, 
vardenafil was reported to prevent the development of diabetes mellitus-associated myocardial 
remodeling, defined as increased myocardial stiffness and worsened diastolic dysfunction.(28) 
Further studies are needed to investigate whether there is a role for such therapies to prevent 
the onset and/or worsening of RV dysfunction in diabetic HFpEF patients. 
There are several limitations that need to be addressed. First, the sample size was small, 
thus we were not able to investigate extensive multivariable associations of comorbidities with 
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RV dysfunction. Second, patients with suspected PH on previous echocardiography were 
referred for invasive evaluation of PH. This resulted in a selection bias with potential 
overrepresentation of PH-HFpEF. The results may therefore not be applicable to the entire 
HFpEF population. Furthermore, established methods to investigate RV diastolic dysfunction 
are lacking. In the present study, invasive pressure-volume loops were not obtained and also 
transtricuspid inflow (i.e. E/A ratio) was not available. Therefore, we could only measure RV 
diastolic function using the tricuspid annular tissue velocity and RV end-diastolic pressure.   
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Figure 1: Echocardiographic assessment of right ventricular tissue velocities and Tei-
index. 
Right ventricular (RV) Tei-index is assessed using the tissue Doppler method by measuring the 
total tricuspid valve closure to opening time (Ta) and right ventricular ejection time (Tb).  Tissue 
Doppler echocardiography is also used to assess the peak systolic tissue velocity (RV s’) and 





Figure 2: Left and right ventricular diastolic dysfunction. Figure 2A: Correlation between 
peak diastolic tissue velocity near the lateral mitral valve annulus, with the peak diastolic tissue 
velocity near the lateral tricuspid valve annulus. Figure 2B: Correlation between peak diastolic 
tissue velocity of the basal septal wall, with the peak diastolic tissue velocity near the lateral 
tricuspid valve annulus. 
 
